Posts by Sandra Ansanay-Alex
Nestlé: Pablo Isla Takes Over Paul Bulcke’s Position as Chairman
The Board of Directors of Nestlé S.A. has announced that Pablo Isla will become Chairman effective 1 October 2025, following Paul Bulcke’s decision to step down from the Board earlier than planned. Paul Bulcke, Chairman of Nestlé, stated: “I have full trust in Nestlé‘s new leadership and firmly believe this great company is well…
Read MorePerivision Secures CHF 2.4M to Re-Imagine Eye Testing with AI and VR
The Vaud-based startup revolutionizes eye testing with a VR headset and an AI powered diagnostic tool Every year, millions of people risk losing their eyesight due to glaucoma and other diseases that often go undetected for too long. Globally, vision loss is estimated to cost the economy more than USD 400B annually, a burden expected…
Read MoreORYL Photonics Closes its Series A Round
ORYL Photonics announces the successful closing of its Series A round. The amount was not disclosed. The round was backed by existing shareholders. Their investment commitment has been achieved in record time (two weeks!). This milestone marks a major step forward for the fast-growing Swiss biotool company, which is pioneering advanced solutions for measuring the…
Read MoreEva.J and Bioressant: Pioneering Swiss Neurocosmetics Through Scientific Innovation
In the sophisticated landscape of contemporary skincare, where scientific rigor meets holistic wellness, Swiss company Bioressant and its flagship brand Eva.J Swiss Organic Neurocosmetics stand as exemplars of innovation at the convergence of neuroscience, dermatology, and biotechnology. Founded by Eva Johnston in Lausanne, this pioneering enterprise has established itself as a trailblazer in the emerging…
Read MoreONWARD Medical Receives CE Mark for ARC-EX®
ONWARD Medical, a Vaud-Based neurotechnology company, has achieved a major milestone with the CE Mark certification of its ARC-EX® System. This approval allows the company to launch its breakthrough spinal cord stimulation therapy across Europe, both for clinical and home use. The first commercial sales are expected in Q4 2025, starting in Germany before expanding…
Read MoreInkocell Therapeutics secures CHF 150,000 from Venture Kick
EPFL spin-off Inkocell Therapeutics, a Swiss biotech startup developing next-generation cell therapies, has secured CHF 150,000 from Venture Kick. The funding will accelerate the development of Inkocell’s first-in-class NK-tailored CAR (chimeric antigen receptor) technology, designed to create effective, safe, off-the-shelf, and affordable therapies for patients with life-threatening diseases. Over the past decade, engineered T-cell…
Read MoreInnosuisse Supports 7 Promising Swiss Health Valley Startups
Innosuisse has selected 39 new Startup Innovation Projects, providing direct funding to early-stage Swiss companies on the cusp of entering the market. These startups are driving innovation across diverse sectors, from pharma and life sciences to industrial applications and beyond. 7 are located in the Swiss Health Valley. Through its Startup Innovation Projects programme,…
Read MoreTop 100 Startups – the Swiss Health Valley is well represented
The Top100 Swiss Startup Ranking showcases the 100 Swiss startups with the most significant potential. Each year, a jury of 100 startup investors selects the most promising companies that are no older than five years after incorporation. The 2025 ranking reflects the strength, diversity, and innovative power of Switzerland’s startup ecosystem,” says Stefan Steiner,…
Read Morecellvie and CSEM Automate Mitochondrial Isolation to Enable Breakthrough Therapies
cellvie, a pioneer in harnessing the therapeutic potential of mitochondria, is developing a novel treatment for ischemia-reperfusion injuries – a condition affecting over 3 million patients annually in Europe and the U.S, in partnership with CSEM Ischemia-reperfusion injuries occur when blood supply returns to tissue after being restricted, causing extensive damage. They are linked…
Read MoreFIF Funding Supports Four Life Sciences Startups: Reverso Therapeutics, Harantech, Vibrant and Joipaw
Four innovative startups from Geneva developing solutions in pet health, life sciences, and digital therapeutics have received support from the FONGIT Innovation Fund (FIF). Harantech and Reverso Therapeutics, both UNIGE spin-offs, along with Vibrant, a Wyss Center project, each received a CHF 50,000 FIF Grant to support the translation of their research into tangible health…
Read More